Upcoming event

Diagnosing the Pathophysiologic Mechanisms of Nocturnal Polyuria

  • An-Sofie Goessaert 1,
  • Louise Krott 2,
  • Piet Hoebeke 1,
  • Johan Vande Walle 3,
  • Karel Everaert 1
1 Urology Department, Ghent University Hospital, Ghent, Belgium 2 Faculty of Medicine, Ghent University, Ghent, Belgium 3 Pediatric Nephrology Department, Ghent University Hospital, Ghent, Belgium

Take home message

Nocturnal polyuria (NP) is a heterogeneous condition involving water diuresis alone, sodium diuresis alone, or a combination of both. A renal function profile based on analysis of eight urine samples collected over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and the timing of high free water or sodium clearance during the night. Use of this test to complement the bladder diary in diagnosing NP might facilitate optimal individualized treatment for patients with NP and bothersome symptoms.

PII: S0302-2838(14)00888-4

DOI: 10.1016/j.eururo.2014.09.003

Background

Diagnosis of nocturnal polyuria (NP) is based on a bladder diary. Addition of a renal function profile (RFP) for analysis of concentrating and solute-conserving capacity allows differentiation of NP pathophysiology and could facilitate individualized treatment.

Objective

To map circadian rhythms of water and solute diuresis by comparing participants with and without NP.

Design, setting, and participants

This prospective observational study was carried out in Ghent University Hospital between 2011 and 2013. Participants with and without NP completed a 72-h bladder dairy. RFP, free water clearance (FWC), and creatinine, solute, sodium, and urea clearance were measured for all participants.

Results

The study participants were divided into those with (n = 77) and those without (n = 35) NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Compared to participants without NP, the NP group exhibited a higher diuresis rate throughout the night (p = 0.015); higher FWC (p = 0.013) and lower osmolality (p = 0.030) at the start of the night; and persistently higher sodium clearance during the night (p < 0.001). The pathophysiologic mechanism of NP was identified as water diuresis alone in 22%, sodium diuresis alone in 19%, and a combination of water and sodium diuresis in 47% of the NP group.

Conclusion

RFP measurement in first-line NP screening to discriminate between water and solute diuresis as pathophysiologic mechanisms complements the bladder diary and could facilitate optimal individualized treatment of patients with NP.

Patient summary

We evaluated eight urine samples collected over 24 h to detect the underlying problem in NP. We found that NP can be attributed to water or sodium diuresis or a combination of both. This urinalysis can be used to adapt treatment according to the underlying mechanism in patients with bothersome consequences of NP, such as nocturia and urinary incontinence.

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Nocturnal polyuria (NP) is an important cause of nocturia in adults and nocturnal enuresis (NE) in children [1] . Results of extensive investigations into the pathophysiology of NE in children have led to individualized treatments with higher efficacy rates and lower side effects[2] and [3]. In adults, NP is diagnosed based on a bladder diary, and treatment is more often based on trial and error than on evidence-based findings [4] . Extrapolation of pediatric data suggests that measurement of a 24-h concentration or renal function profile (RFP) for analysis of the nocturnal diuresis rate, concentrating capacity, and solute-conserving capacity could allow differentiation of NP pathophysiology as a guide to individualized treatment of adult patients with NP, as in children with NE [5] .

In studies with limited participants, water diuresis and/or solute diuresis were identified as pathophysiologic mechanisms that play a role in adult NP [5] . Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, as seen in patients with obstructive sleep apnea and patients with heart failure [6] . Impaired circadian rhythms for these hormones also affect the circadian rhythms for renal clearance of free water and solutes. Healthy children exhibit marked circadian rhythms for hormones involved in urine production [7] . It is believed that a loss of these circadian rhythms in older patients is a physiologic aging effect. However, the consequences can be pathologic, for example when NP leads to bothersome nocturia affecting general health and sleep quality[8] and [9]. In younger adults, circadian rhythms are assumed to be somewhere in between those of children and older individuals, but evidence is limited.

The aims of this study were:

  • 1. To map circadian rhythms for water and solute diuresis in populations with and without NP to establish a reference for normal circadian rhythms in an adult population;
  • 2. To evaluate the use of RFPs in the diagnostic approach to NP; and
  • 3. To evaluate the distribution of different pathophysiologic mechanisms of NP among patients.

2.1. Patient selection and data collection

A prospective observational study was designed and carried out in Ghent University Hospital, Belgium, between October 2011 and May 2013. Participants were recruited via posters, brochures, and consultations. There were no specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. On the basis of bladder diary results, participants were assigned to subgroups with or without NP. A modified International Continence Society (ICS) definition of NP was used: NP index (NPI) >20% in subjects up to 35 yr of age; NPI > 33% in those aged ≥65 yr; and for middle-aged subjects the cutoff values were between 20% and 33% (1% rise for every 2.5 yr of age) [10] . An alternative definition of NP based on nocturnal urine production (NUP) of >90 ml/h was used for comparison. [11] Exclusion criteria were 24-h polyuria (>40 ml/kg over 24 h) and severe urinary incontinence.

Subjects were asked to complete a bladder diary to collect a RFP and a blood sample was taken. Patients who failed to complete the three studies were excluded.

Participants completed a 72-h bladder diary, not necessarily consecutively. The data collected included micturition and drinking frequency and volumes, as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume comprised the sum of all nocturnal micturition and the first morning micturition. Participants with urinary incontinence had to report the frequency and an indication of the quantity of urinary leaks.

RFPs were recorded separately from the bladder diary in terms of 24-h urinalysis for urine samples collected every 3 h for analysis of diuresis rate, osmolality, and sodium, urea, and creatinine concentrations. Micturition volume at the time of sample collection was recorded, as well as volumes for all interim micturition. The test was started in the morning, with the first sample collected 3 h after the first morning micturition. Urinary sample U1 was collected between 9 and 11am, U2 between 12 and 2pm, U3 between 3 and 5pm, U4 between 6 and 8pm, U5 between 9 and 11pm, U6 between 12 and 2am, U7 between 3 and 5am, and U8 between 6 and 8am. U1–U5 were considered daytime samples, and U6–U8, nighttime samples.

Serum osmolality, creatinine, sodium, and urea were analyzed and the results were used to calculate the renal clearance of each of these substances (Usubst × urine flow/Psubst).

The general assessment for each participant included uroflowmetry and a bladder ultrasound scan to evaluate the post-void residual volume. Participants were asked to fill out the female or male version of the ICI questionnaire on lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-MLUTS, respectively) to assess storage, voiding, and incontinence symptoms.

The study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed, and written informed consent to study participation was obtained from all subjects.

2.2. Statistical analysis

Statistical analysis was performed using SPSS v.21 for Windows (IBM Corp, Armonk, NY, USA). The median, interquartile range, and frequency were recorded as descriptive statistical parameters. Differences between groups were assessed using the chi-square test for dichotomous variables and the Mann-WhitneyUtest for nonparametric variables. Comparisons within groups were performed using the Wilcoxon signed rank test for two related samples, and the Kruskall-Wallis test for more than two related samples. Linear regression analysis and receiver operating characteristic (ROC) curves were used to determine cutoff values. Apvalue <0.05 was considered statistically significant.

The results for 112 subjects were eligible for analysis; 77 with NP and 35 without NP. The mean age was 57 yr (SD 16 yr) and 41% of the participants were female. Significantly higher nocturnal voided volume (NVV;p < 0.001) and nighttime frequency (p < 0.006) were observed in the NP group ( Table 1 ).

Table 1 Characteristics of participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77) p value
Age (yr) 57 (49–66) 61 (50–68) 0.775
Gender, male/female (% female) 18/17 (49) 49/30 (38) 0.279
Body mass index (kg/m2) 24 (22–27) 25 (23–27) 0.514
Peak flow rate (ml/s) 18 (8–59) 16 (5–70) 0.143
Post-voiding residual volume, % > 10 ml; ml 34; 36 (15–157) 38; 40 (11–209) 0.354
Female lower urinary tract symptoms (women only)
 Storage symptoms (max 15) 3 (0–7) 4 (0–10) 0.493
 Voiding symptoms (max 12) 0 (0–6) 1 (0–6) 0.115
 Incontinence symptoms (max 20) 2 (0–7) 1 (0–14) 0.134
Male lower urinary tract symptoms (men only)
 Voiding symptoms (max 20) 5 (0–12) 8 (0–16) 0.214
 Incontinence symptoms (max 24) 3 (0–9) 5 (0–19) 0.707
Drinking volume (ml) 1794 (1498–2072) 1710 (1333–2107) 0.462
24-h urine volume (ml) 1610 (1390–2048) 1773 (1388–2210) 0.376
Nocturnal voided volume (ml) 313 (233–456) 643 (449–865) 0.001 *
Mean 24-h functional bladder capacity (ml) 212 (171–267) 196 (150–285) 0.557
Maximum voided volume (ml) 353 (277–407) 350 (267–480) 0.613
Voiding frequency daytime 7 (6–9) 7 (6–9) 0.472
Voiding frequency nighttime 0 (0–2) 1 (0–3) 0.006*

* p < 0.05, Mann-Whitney U test.

Data are presented as median (interquartile range) unless indicated otherwise.

3.1. Reference population

Table 2 shows data for daytime and nighttime diuresis rates, free water clearance (FWC), osmolality, and creatinine, solute, sodium, and urea clearance for participants without NP. The nighttime diuresis rate was significantly lower than the daytime rate (p = 0.005). Solute (p < 0.002) and sodium (p = 0.025) clearance rates and the sodium excretion rate (p = 0.031) were significantly lower at night. Urea clearance was also lower at night (p < 0.001). FWC and creatinine clearance did not differ significantly between day and night.

Table 2 Daytime and nighttime parameters for participants with and without nocturnal polyuria (NP)

  No NP (n = 35) NP (n = 77)
  Daytime Nighttime p value Daytime Nighttime p value
Diuresis rate (ml) 1.2 (0.9–1.8) 1.0 (0.8–1.3) 0.005 * 1.3 (0.9–1.7) 1.4 (0.9–1.8) 0.433
Free water clearance (ml/min) −0.8 (−1.4 to 0.4) −0.8 (−1.2 to 0.5) 0.291 −1.0 (−1.6 to 0.6) −0.7 (−1.3 to 0.3) 0.021 *
Osmolality (mosm/kg) 550 (422–787) 626 (444–782) 0.376 594 (481–729) 498 (396–656) 0.001 *
Creatinine clearance (ml/min) 118 (98–156) 108 (87– 54) 0.156 128 (96–149) 115 (84–147) 0.036 *
Solute clearance (ml/min) 2.4 (2.0–2.9) 2.0 (1.6–2.4) 0.002 * 2.5 (1.8–3.0) 2.3 (1.7–2.8) 0.023 *
Sodium clearance (ml/min) 0.9 (0.7–1.1) 0.7 (0.5–1.1) 0.025 * 1.0 (0.7–1.2) 1.0 (0.7–1.2) 0.592
Sodium excretion (mmol/l)/(mg/dl creatine) 6.6 (6.0–7.5) 5.8 (4.6–6.4) 0.031 * 6.3 (5.4–7.3) 6.5 (5.2–7.3) 0.012 *
Urea clearance (ml/min) 57 (41–71) 18 (13–25) 0.001 * 53 (37–67) 19 (14–25) 0.001 *

* p < 0.05, within-group Wilcoxon test.

p < 0.05, between-group Mann-Whitney U test.

Data are presented as median (interquartile range).

Figure 1 shows a more detailed representation of the circadian rhythms. The diuresis rate during the daytime was relatively stable (p = 0.245) and then decreased at night (U6–U8,p = 0.043). No significant daytime variation was seen for FWC, osmolality, solute, sodium or urea clearance. There were significant nocturnal decreases in solute (p < 0.001), sodium (p = 0.006) and urea clearance (p = 0.013). A 24-h variation (U1–U8) was seen for the diuresis rate and for solute, sodium, and urea clearance.

gr1

Fig. 1 Circadian rhythms for (A) diuresis rate, (B) free water clearance, (C) osmolality, (D) solute clearance, (E) sodium clearance, and (F) urea clearance for participants with and without nocturnal polyuria (NP) according to eight urine samples collected over 24 h. Daytime urine samples were taken at 9–11am(U1), 12–2pm(U2), 3–5pm(U3), 6–8pm(U4), and 9–11pm(U5). Nighttime urine samples were taken at 12–2am(U6), 3–5am(U7), and 6–8am(U8). The table above each plot showspvalues for the within-group Kruskall-Wallis test; values in italics are significant. Reversed rhythms are evident for all variables except urea clearance for the NP group compared to the reference group (p < 0.05). *p < 0.05 for NP versus the reference (no NP) group (Mann-WhitneyUtest).

3.2. NP population

Reversed day-night rhythms for concentrations were observed in participants with NP ( Table 2 ). Comparison of nighttime with daytime values revealed no significant decrease in the diuresis rate (p = 0.433), a significant increase in FWC (p = 0.021), and a significant decrease in osmolality (p < 0.001). Creatinine clearance was lower at nighttime compared to daytime (p = 0.036). Whereas solute clearance was significantly lower at night (p = 0.023), sodium clearance remained at the same levels as during the day (p = 0.592), and sodium excretion increased at night (p = 0.012). Compared to the reference population without NP, significant differences were observed for the nighttime diuresis rate (p = 0.019) and sodium excretion (p = 0.007).

Variations during daytime and nighttime ( Fig. 1 ) revealed a stable diuresis rate during both daytime and nighttime for participants with NP. FWC and osmolality showed no significant variation during daytime; at night, FWC decreased from the initial peak (p < 0.001) and osmolality increased from the initial drop (p < 0.001). The reverse was seen for solute, sodium and urea clearance, with significant increases during the daytime (p = 0.026,p < 0.001,p = 0.021, respectively), but no variation during the nighttime. All parameters exhibited significant 24-h variation.

3.3. Reference versus NP participants

Comparison of the reference and NP participants revealed significant differences during the night ( Fig. 1 ). At the start of the night (U6), higher FWC (p = 0.013) and lower osmolality (p = 0.030) were observed in the NP group. In the middle of the night (U7), the diuresis rate remained high in the NP group, whereas it decreased in the reference group (p = 0.049); this trend continued until the end of the night (U8,p = 0.015). A difference in sodium clearance between the groups started at U7 (p < 0.001) and continued at U8 (p = 0.002). Solute clearance was higher in participants with NP compared to those without at U7 (p = 0.013); urea clearance did not differ at any point between the groups.

3.4. Pathophysiologic mechanisms of NP

ROC analysis to discriminate between the NP and reference groups revealed an area under the curve (AUC) of 65% (p = 0.013) for nocturnal FWC (U6), with a cutoff value of −0.85 ml/min corresponding to sensitivity of 66% and specificity of 60%. For nocturnal sodium clearance (U7) the AUC was 72% (p < 0.001), with 0.65 ml/min corresponding to sensitivity of 69% and specificity of 63%.

Figure 2 A shows the distribution of high FWC and/or high sodium clearance rates in participants with and without NP using the cutoff values with the highest sensitivity and specificity according to ROC analysis. None of the pathophysiologic mechanisms applied to 43% of the reference group compared to 12% of the NP group (p < 0.001); no significant difference was found for high FWC alone or high sodium clearance alone. The combination of both was significantly higher in participants with NP (47%) than in the reference group (20%;p = 0.022).

gr2

Fig. 2 Distribution of the pathophysiologic mechanisms underlying nocturnal polyuria (NP) according to two different definitions: (A) NP index >20–33% and (B) nocturnal urine production >90 ml/h. FWC = free water clearance.

Using the NUP definition of NP of >90 ml/h, ROC analysis revealed 76 subjects without NP and 36 with NP. For nocturnal FWC (U6) the AUC was 64%, with highest sensitivity (71%) and specificity (62%) for a cutoff value of −0.65 ml/min. For nocturnal sodium clearance (U7) the AUC was 67%; a cutoff value of 0.77 ml/min resulted in sensitivity and specificity of 60%.

According to these cutoff values, NP was attributed to high FWC alone in 34%, high sodium clearance alone in 23%, and a combination in 37% of the NP group.

NP can be considered a normal part of the aging process; it is known that loss of circadian rhythms for diuresis-regulating hormones and renal concentrating and sodium-conserving capacity occurs with advancing age[12] and [13]. However, the NP population in the present study did not consist of only older people (age range 18–85 yr), indicating that this process had already started at a younger age in a considerable proportion of the study population.

Healthy children exhibit a pronounced circadian rhythm, with a nocturnal decrease in the diuresis rate and excretion of solutes, and a nocturnal increase in urinary osmolality [14] . Although less pronounced, the adult population without NP exhibits a similar pattern for the diuresis rate and solute, sodium, and urea clearance, with a stable level during the day and a decrease during the night. FWC and osmolality, however, showed no significant circadian rhythm at all. Findings in our reference population suggest that the circadian rhythm for diuresis progressively disappears and NP starts from the age of 20–30 yr.

This study confirms that NP is a heterogeneous condition, in which water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night. Herek et al. [5] conducted a similar study to evaluate daytime and nighttime parameters for 24-h urine samples collected from 29 female patients with NP (mean age 74 yr) and described these three pathophysiologic subgroups of NP. This encourages categorization of NP to optimize the required treatment. A great advantage of the approach used in our study, with eight urine samples collected over 24 h, is that we can differentiate the timing of the pathophysiologic mechanisms involved. An increase in FWC and a decrease in osmolality were found only at the start of the night (U6), whereas sodium clearance in NP remained high throughout the night (U7 and U8).

Treatment with a V2 agonist is useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a high V2 agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2am. Vasopressin can be suppressed by excessive fluid intake, so polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia [15] . In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body's sodium load is handled during the day, leading to lower sodium excretion at night and thus lower NUP [16] . In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP[17] and [18]. Treatment of NP with diuretics has only been studied in small samples in children with enuresis and in elderly individuals with nocturia. Nevertheless, these studies provide enough evidence to warrant large case-control trials to confirm the beneficial effect of diuretics on increased nocturnal sodium and water diuresis.

To evaluate the proportion of the study sample that qualifies for antidiuretic or diuretic treatment or both, ROC analysis was applied to the most representative samples for FWC and sodium clearance, U6 and U7, respectively. Using cutoff values with the best balance of sensitivity and specificity, almost half of the NP patients have combined water and solute diuresis and could benefit from a combination therapy, approximately 20% qualify for antidiuretic treatment, and another 20% qualify for diuretic treatment alone.

However, since the relevance of the ICS definition for NP is under discussion, ROC analysis was also applied for the NUP definition of >90 ml/h [19] . This resulted in higher cutoff values for FWC and sodium clearance. With these cutoff values, the distribution was approximately 30% for each of the subgroups, with no pathophysiologic mechanism identified for only 6% of the NP group. The most remarkable difference was a significantly lower proportion of the sample diagnosed with NP compared to the NPI > 20–33% definition (31% vs 69%, respectively).

These cutoff values are not intended to be extrapolated to a general NP population; rather, they serve as an indication of the distribution of the pathophysiologic mechanisms of NP.

4.1. Study limitations

Limitations of our study include the limited number of participants and the fact that comorbidities such as diabetes and arterial hypertension were not taken into account. Although the study population represents the population seen in clinical practice, we recommend larger studies in well-defined subgroups of NP patients to evaluate RFP differences and usable cutoff values.

NP is more than just an increase in overnight diuresis; it is a heterogeneous condition with two different underlying mechanisms: water diuresis and sodium diuresis. A large percentage of patients exhibit variable degrees of both characteristics.

RFP involving collection of eight urine samples over 24 h allows differentiation of the pathophysiologic mechanisms underlying NP and of the timing of high FWC or high sodium clearance during the night. Use of this test complements a bladder diary in diagnosing the characteristics of NP.

Author contributions: An-Sofie Goessaert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Vande Walle, Everaert, Goessaert.

Acquisition of data: Goessaert, Everaert, Krott.

Analysis and interpretation of data: Goessaert, Vande Walle, Everaert, Krott.

Drafting of the manuscript: Goessaert, Everaert, Vande Walle.

Critical revision of the manuscript for important intellectual content: Everaert, Vande Walle, Hoebeke.

Statistical analysis: Goessaert, Everaert.

Obtaining funding: Vande Walle, Everaert.

Administrative, technical, or material support: Hoebeke, Everaert.

Supervision: Vande Walle, Everaert.

Other (specify): None.

Financial disclosures: An-Sofie Goessaert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: An-Sofie Goessaert received a grant from Ferring. Karel Everaert is a consultant and speaker for Ferring and received grants from Ferring, Bard and Pfizer. Johan Vande Walle is a consultant and speaker for Ferring, is involved in trials and received travel grants from Ferring. Piet Hoebeke and Louise Krott have nothing to disclose.

Funding/Support and role of the sponsor: None.

  • [1] P. Abrams, A. Mattiasson, P. van Kerrebroeck, G. Robertson. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn. 2004;23:466-467
  • [2] T. Neveus. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26:1207-1214 Crossref
  • [3] P. van Kerrebroeck, H. Hashim, T. Holm-Larsen, D. Robinson, N. Stanley. Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract. 2010;64:807-816 Crossref
  • [4] A. Rembratt, J.P. Norgaard, K.E. Andersson. Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2003;91:45-50 Crossref
  • [5] J. Herek, M. Fitzgerald, M. Mohindra, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon. 2010;2:526-531
  • [6] K.P. Van, K.E. Andersson. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5
  • [7] K. Kamperis, M.N. Hansen, S. Hagstroem, G. Hvistendahl, J.C. Djurhuus, S. Rittig. The circadian rhythm of urine production, and urinary vasopressin and prostaglandin E2 excretion in healthy children. J Urol. 2004;171:2571-2575 Crossref
  • [8] D. Fonda. Nocturia: a disease or normal ageing?. BJU Int. 1999;84:13-15
  • [9] M.A. Hofman, D.F. Swaab. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev. 2006;5:33-51 Crossref
  • [10] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int. 2002;90:11-15 Crossref
  • [11] B. van Doorn, M.H. Blanker, E.T. Kok, P. Westers, J.L.H.R. Bosch. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-547 Crossref
  • [12] M. Epstein. Aging and the kidney. J Am Soc Nephrol. 1996;7:1106-1122
  • [13] M. Miller. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329
  • [14] S. Rittig, U.B. Knudsen, J.P. Norgaard, E.B. Pedersen, J.C. Djurhuus. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671
  • [15] J.P. Weiss, K.V. Juul, A.J. Wein. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19-S24
  • [16] K. Fujikawa, M. Kasahara, Y. Matsui, H. Takeuchi. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol. 2001;35:310-313
  • [17] A. De Guchtenaere, C. Vande Walle, P. Van Sintjan, et al. Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning. J Urol. 2007;178:2635-2639 Crossref
  • [18] F.G. Fu, H.J. Lavery, D.L. Wu. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:312-316 Crossref
  • [19] Hofmeester I, Kollen BJ, Steffens MG, et al. Impact of the International Continence Society report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review. BJU Int. In press. http://dx.doi.org/10.1111/bju.12753 .

Commented by Prof. Antonella Giannantoni

In the present article, Goessaert et al. describe the circadian rhythms of water and solute diuresis in an adult population with and without nocturnal polyuria (NP); they were also able to identify different pathopysiologic mechanisms for NP. Between October 2011 and May 2013, the authors conducted an observational study in Ghent University Hospital, Belgium. Participants were recruited via posters, brochures and consultation, without specific inclusion criteria. Exclusion criteria were neurogenic bladder and/or bladder/urethra surgery. Subjects were asked to complete a 72 hour bladder diary, and a blood sample was taken. The collected data included micturition, drinking frequency and volumes as well as the time at which the participant went to bed and got up in the morning. The nocturnal volume included the sum of all nocturnal micturitions and the first morning micturition. Urine samples were collected every 3 hours for the analysis of diuresis rate, osmolality as well as sodium, urea and creatinine concentrations. Micturition volume at the time of sample collection and the volumes for all interim micturitions were recorded. The results of 112 subjects were available for the analysis; 77 presented with NP and 35 without NP. The mean age was 57 years, 41% of the participants were female.
In individuals without NP, the nighttime diuresis rate was significantly lower than the daytime rate. Solute and sodium clearance rates as well as the sodium excretion rate were significantly lower at night. Urea clearance was also lower at night. Creatinine clearance did not differ significantly between day and night. The diuresis rate was relatively stable during the day and decreased at night. In patients with NP, no significant decrease in the diuresis rate during the night was observed. A significant increase in free water clearance and a significant decrease in osmolality were detected. Creatinine clearance was lower at nighttime compared to daytime. Sodium clearance remained at the same levels as during the day, whereas sodium excretion increased at night.

The results of this important study confirm that NP is a heterogeneous condition in which the underlying cause consists of water diuresis, solute diuresis or a combination of both. Water diuresis is represented by high free water clearance and low osmolality at night. For solute diuresis, the main mechanism seems to be increased sodium clearance during the night. Importantly, an increase in free water clearance and a decrease in osmolality were only found at the start of the night, whereas sodium clearance in NP remained high throughout the night.

These results are really crucial from a therapeutic point of view. Water diuresis is associated with impairment of vasopressin action, whereas solute diuresis can be due to increased atrial natriuretic peptide secretion, a condition observed in patients with obstructive sleep apnea and in those with hearth failure. A loss of these circadian rhythms has just been found in children with nocturnal enuresis, but it can also be identified in old patients as a physiologic ageing effect. Indeed, consequences become pathologic when NP leads to bothersome nocturia affecting general health, sleep quality and quality of life. Nocturnal sodium diuresis may require treatment that restores a normal sodium clearance pattern, i.e. the patient should take diuretics in the morning. In the case of patients with NP due to excessive water diuresis who have positive nocturnal free water clearance and/or low nocturnal osmolality, treatment with a V2 agonist can be useful. In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in nocturnal urine production.

Commented by Professor Karl-Erik Andersson
The diagnosis of nocturnal polyuria (NP) in adults is usually based on a bladder diary, which gives limited pathophysiological information (Cornu et al., 20121; van Kerrebroeck and Andersson, 20142). Herek et al. (2010)3 performed a retrospective chart review of patients who were referred to the clinic because of troublesome nocturia later diagnosed as NP. The authors analyzed, in addition to the diary, the patterns of solute and water excretion and found that their patients fell into one of three categories: those with increased nocturnal solute diuresis, those with decreased nocturnal free water reabsorption, and those with nocturnal mixed diuresis, They concluded that “A clinical categorization scheme based on these excretion patterns may help direct the clinician in choosing an appropriate therapy.” That this can be the case was shown by the excellent prospective observational study of Goessaert et al. (2014)4. The investigators combined a bladder diary with a renal function profile (RPF) and undertook a comprehensive testing of multiple parameters relevant to salt and water handling at regular intervals during the day and at night. Their findings showed circadian variation in salt and water handling, and distinct changes in symptomatic patients. Compared to subjects without NP, the NP group exhibited a higher diuresis rate throughout the night, higher free water clearance (FWC) and lower osmolality at the start of the night, and persistently higher sodium clearance during the night. The pathophysiologic mechanism of NP was identified as water diuresis alone in 22%, sodium diuresis alone in 19%, and a combination of water and sodium diuresis in 47% of the NP group.

The results of Gossaert et al. (2014)4 confirm that NP is a heterogeneous condition that starts from an early age, and show that water diuresis, solute diuresis, or a combination of both is the underlying cause. Water diuresis is represented by high FWC and low osmolality at night. For solute diuresis, the driving force seems to be increased sodium clearance during the night.

The authors clearly show that RFP measurement in first-line NP screening can discriminate between water and solute diuresis as pathophysiologic mechanisms, and that it complements the bladder diary. As a consequence this approach might facilitate optimal individualized treatment of patients with NP. Thus, as discussed by the authors, a vasopressin V2 receptor agonist can be useful in NP patients with excessive water diuresis who have positive nocturnal FWC and/or low nocturnal osmolality, which is an indication of suppressed vasopressin. The time window in which a highV2 receptor agonist response is expected is at the start of the night, which coincides with high FWC and low osmolality between 12 and 2 AM. Since vasopressin can be suppressed by excessive fluid intake, polydipsia has to be ruled out before starting V2 agonist treatment because of the risk of hyponatremia. In the case of nocturnal sodium diuresis, treatment to restore a normal sodium clearance pattern could be indicated. By taking diuretics during the day, the body’s sodium load is handled during the day, leading to lower sodium excretion at night and thus lower nocturnal urine production. In the case of combined water and sodium diuresis, a combination of diuretics in the morning and antidiuretics in the evening might result in the desired decrease in NUP. However, it should be underlined that before starting any treatment of NP/nocturia, full consideration should be given to any of the many medical conditions that can be responsible for the symptoms (Gulur et al., 2011)5.

The results of Gossaert et al4. not only increase our knowledge about circadian rhythms of water and solute diuresis in normal adult individuals and in NP, but also opens up new possibilities to diagnose and treat the condition based on pathophysiological mechanisms. Even if their approach is experimental and impractical for use in everyday practice, it gives the directions for further studies in the field.

References
[1] Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, Tubaro A, Madersbacher S. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management–a systematic review and meta-analysis. Eur Urol. 2012 Nov;62(5):877-90.

[2] van Kerrebroeck P and Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn 2014;33(Suppl 1): S2–5.

[3] Herek J, Fitzgerald M, Mohindra M, et al. Solute and water excretion patterns in patients with nocturnal polyuria. Nephrourol Mon 2010;2:526–31.

[4] Goessaert A-S, Krott L, Hoebeke P, Vande Walle J, Everaert K. Diagnosing the pathophysiologic mechanisms of nocturnal polyuria. Eur Urol 2015;67:283–8.

[5] Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease. BJU Int 2011;107:702–13.